Medicare billing address
CMS Medicare provider billing file
1095 Rydal RdSuite 100
Rydal, PA 19046
CMS public data · NPI 1104863091
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Stuart M Lubinski, M.D.
Specialty
Credential
M.D.
NPI
1104863091
Primary source state
PA
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Stuart M Lubinski, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
1095 Rydal RdCMS Doctors & Clinicians file
1095 Rydal RdCMS Doctors & Clinicians file
1200 Old York RdCMS Doctors & Clinicians file
1200 Old York RdIn the 2024 CMS provider billing file, this NPI had 533 Medicare beneficiaries and 20,172 total services. The average beneficiary age was 74, and the average HCC risk score was 1.5.
Total Medicare allowed amount
$561,241.75
Total Medicare payment amount
$441,250.69
Medicare beneficiaries
533
Total services
20,172
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
75%
CMS beneficiary-panel share
Anxiety
32%
CMS beneficiary-panel share
Mood disorders
29%
CMS beneficiary-panel share
Chronic kidney disease
28%
CMS beneficiary-panel share
Diabetes
28%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, vedolizumab, intravenous, 1 mg | 15,900 | $21.90 |
| Injection, infliximab, excludes biosimilar, 10 mg | 3,250 | $31.42 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 241 | $130.96 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 101 | $131.93 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 91 | $79.45 |
| New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | 69 | $169.72 |
| Administration of chemotherapy into vein, 1 hour or less | 55 | $118.71 |
| Administration of chemotherapy into vein, each additional hour | 55 | $28.42 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 53 | $64.61 |
| Biopsy of large bowel using a flexible endoscope | 51 | $92.48 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1104863091. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Pantoprazole Sodium | Pantoprazole Sodium | 159 | 439 | $2,076.70 |
| 2 | Stelara | Ustekinumab | 92 | 131.9 | $2,520,012.71 |
| 3 | Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,Mag Sulfates | 91 | 91 | $5,917.14 |
| 4 | Mesalamine | Mesalamine | 63 | 146.6 | $39,403.51 |
| 5 | Famotidine | Famotidine | 50 | 127.2 | $778.01 |
| 6 | Omeprazole | Omeprazole | 46 | 132 | $540.72 |
| 7 | Colestipol Hcl | Colestipol Hcl | 37 | 87 | $3,002.64 |
| 8 | Budesonide Er | Budesonide | 29 | 29 | $28,925.34 |
| 9 | Budesonide Ec | Budesonide | 23 | 63 | $7,204.08 |
| 10 | Prednisone | Prednisone | 23 | 24.6 | $99.12 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
Perelman School Of Med At The University Of Pennsylvania
Graduation year
1993
Group/practice field
Methodist Associates In Healthcare, Inc
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.